RELEASE-2: Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
Study Details
Study Description
Brief Summary
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the subject using the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) and by the Investigator using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) will be eligible. The eligibility of the buttocks will be confirmed on Day 1. Once the eligibility of the buttocks is confirmed, subjects will be randomly assigned to a treatment group (EN3835 0.84 mg per buttock or placebo) in a 1:1 ratio within an investigational site. Each subject will receive a treatment course which consists of up to 3 treatment visits (sessions), separated by 21 days (ie, Days 1, 22, and 43). Each treatment visit will consist of 12 injections (0.3 mL per injection of EN3835 0.07 mg/injection or placebo; 0.84 mg in 3.6 mL per buttock) in each of the two buttocks for a total volume of 7.2 mL (1.68 mg). Selection of dimples to be treated in the buttocks will be at the discretion of the Investigator. End of study will occur at study day 71.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: EN3835 Active EN3835 0.84mg (Collagenase Clostridium Histolyticum) |
Biological: EN3835
Collagenase clostridium histolyticum
|
Placebo Comparator: Placebo Placebo |
Biological: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- 2-level Composite Responders for the Target Buttock [Day 71]
Proportion of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-level composite responder is defined as a participant with improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock. A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder.
Secondary Outcome Measures
- 1-level PR-PCSS Responders of the Target Buttock [Day 71]
Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).
- 2-level PR-PCSS Responders of the Target Buttock [Day 71]
Improvement in cellulite severity of the Target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).
- 1-level Composite Responders of the Target Buttock [Day 71]
Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).
- 2-level Composite Responders of the Non-target Buttock [Day 71]
Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician -Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe).
- 1-level SSRS Responders [Day 71]
Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from "0" (Extremely Dissatisfied) to "6" (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied [4], Very Satisfied [5], or Extremely Satisfied [6]) with the appearance of the cellulite on her buttocks at Day 71.
- Change From Baseline in PR-CIS Total Score [Day 71]
Patient-Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from "0" (Not at all) to "10" (Extremely). The PR-CIS total score is the sum of individual item scores and can range from "0" to "60" with higher numbers reflecting a more negative impact from the cellulite. A responder is defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at evaluation time point. A negative change from baseline indicates an improvement in cellulite severity.
- 1-level S-GAIS Responders of Target Buttock [Day 71]
Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with ≥1-level improvement (Improved, Much Improved or Very Improved) in S-GAIS assessment of the Target Buttock.
- 2-level S-GAIS Responders of Target Buttock [Day 71]
Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock.
- PR-PCSS Rating for the Target and Non-target Buttock by Visit [Day 71]
The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant's cellulite. The ratings range from "0" (None) to "4" (Severe).
- Subjects Satisfaction With Cellulite Treatment [Day 71]
A 1-level Subject Satisfaction Responder is defined as a participant who is at least satisfied (Satisfied [+1], or Very Satisfied [+2]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite.
Other Outcome Measures
- Serum Antibody Positivity by Visit [Day 1 - Day 71]
Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit.
- Overall Antibody Titer Levels by Visit [Day 1 - Day 71]
Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is "<10". Only seropositive participants are summarized.
- Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles [Day 71]
Q1 and Q4 are based on the ADA titer levels.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntarily sign and date an informed consent agreement
-
Be a female ≥18 years of age
-
At Screening visit, have 2 bilateral buttocks with each buttock having:
-
a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and
-
a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)
-
At Day 1 visit, have 2 bilateral buttocks with each buttock having:
-
a score of 3 or 4 (moderate or severe) as reported by the subject (PR-PCSS), and
-
a score of 3 or 4 (moderate or severe) as reported by the Investigator (CR-PCSS)
-
Be willing to apply sunscreen to the buttocks before each exposure to the sun while participating in the study (ie, Screening through end of study)
-
Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at Screening
-
Have a negative serum pregnancy test at Screening and a negative urine pregnancy test before injection of study drug and be using a stable and effective contraception method (eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the Investigator; or post-menopausal for at least 1 year; or be surgically sterile
-
Be willing and able to cooperate with the requirements of the study
-
Be able to read, complete and understand the patient-reported outcomes rating instruments in English
Exclusion Criteria:
-
Has any of the following systemic conditions:
-
Coagulation disorder
-
Evidence or history of malignancy (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years
-
History of keloidal scarring or abnormal wound healing
-
Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. Any questions about concurrent diseases should be discussed with the Medical Monitor
-
Evidence of clinically significant abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values
-
Has any of the following local conditions in the areas to be treated:
-
History of lower extremity thrombosis or post-thrombosis syndrome
-
Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated
-
Inflammation or active infection
-
Severe skin laxity, flaccidity, and/or sagging
-
Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer
-
Has a tattoo and/or a mole located within 2 cm of the site of injection
-
Requires the following concomitant medications before or during participation in the trial:
- Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug
-
Has used any of the following for the treatment of EFP on a buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
-
Liposuction in a buttock during the 12-month period before injection of study drug
-
Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; buttock implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) within a buttock during the 12-month period before injection of study drug
-
Any investigational treatment for EFP on a buttock during the 12-month period before the injection of study drug
-
Endermologie or similar treatments within a buttock during the 6-month period before injection of study drug
-
Massage therapy within a buttock during the 3-month period before injection of study drug
-
Creams (eg, Celluvera™, TriLastin®) and/or home therapies to prevent or mitigate EFP within a buttock during the 2-week period before injection of study drug
-
Is presently nursing or providing breast milk
-
Intends to become pregnant during the study
-
Intends to initiate an intensive sport or exercise program during the study
-
Intends to initiate a weight reduction program during the study
-
Intends to use tanning spray or tanning booths during the study
-
Has received an investigational drug or treatment within 30 days before injection of study drug
-
Has a known systemic allergy to collagenase or any other excipient of study drug
-
Has received any collagenase treatments at any time prior to treatment
-
Was a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, and/or EN3835-205
-
Any other condition(s) that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Endo Clinical Trial Site #1 | Glendale | Arizona | United States | 85308 |
2 | Endo Clinical Trial Site #2 | North Little Rock | Arkansas | United States | 72116 |
3 | Endo Clinical Trial Site #3 | Beverly Hills | California | United States | 90210 |
4 | Endo Clinical Trial Site #4 | Murrieta | California | United States | 92562 |
5 | Endo Clinical Trial Site #5 | Newport Beach | California | United States | 92663 |
6 | Endo Clinical Trial Site #6 | San Diego | California | United States | 92121 |
7 | Endo Clinical Trial Site #7 | Greenwood Village | Colorado | United States | 80111 |
8 | Endo Clinical Trial Site #8 | Coral Gables | Florida | United States | 33146 |
9 | Endo Clinical Trial Site #9 | Miami | Florida | United States | 33137 |
10 | Endo Clinical Trial Site #10 | Nampa | Idaho | United States | 83651 |
11 | Endo Clinical Trial Site #11 | Carmel | Indiana | United States | 46032 |
12 | Endo Clinical Trial Site #12 | Metairie | Louisiana | United States | 70006 |
13 | Endo Clinical Trial Site #13 | New Orleans | Louisiana | United States | 70124 |
14 | Endo Clinical Trial Site #14 | Warren | Michigan | United States | 48088 |
15 | Endo Clinical Trial Site #15 | Montclair | New Jersey | United States | 07042 |
16 | Endo Clinical Trial Site #16 | East Setauket | New York | United States | 11733 |
17 | Endo Clinical Trial Site #17 | New York | New York | United States | 10016 |
18 | Endo Clinical Trial Site #18 | Cincinnati | Ohio | United States | 45212 |
19 | Endo Clinical Trial Site #19 | Nashville | Tennessee | United States | 37215 |
20 | Endo Clinical Trial Site #20 | Austin | Texas | United States | 78759 |
21 | Endo Clinical Trial Site #21 | Beaumont | Texas | United States | 77701 |
22 | Endo Clinical Trial Site #22 | Houston | Texas | United States | 77494 |
23 | Endo Clinical Trial Site #23 | San Antonio | Texas | United States | 78229 |
24 | Endo Clinical Trial Site #24 | Salt Lake City | Utah | United States | 84101 |
25 | Endo Clinical Trial Site #25 | Lynchburg | Virginia | United States | 24501 |
Sponsors and Collaborators
- Endo Pharmaceuticals
Investigators
- Study Director: Michael McLane, Endo Pharmaceuticals
Study Documents (Full-Text)
More Information
Publications
None provided.- EN3835-303
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock 1.68 mg Total Dose | Placebo-control |
Period Title: Overall Study | ||
STARTED | 214 | 208 |
COMPLETED | 186 | 191 |
NOT COMPLETED | 28 | 17 |
Baseline Characteristics
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo | Total |
---|---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock 1.68 mg Total Dose | Placebo-control | Total of all reporting groups |
Overall Participants | 214 | 206 | 420 |
Age (years) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [years] |
47.7
(10.62)
|
45.7
(11.16)
|
46.7
(10.92)
|
Sex: Female, Male (Count of Participants) | |||
Female |
214
100%
|
206
100%
|
420
100%
|
Male |
0
0%
|
0
0%
|
0
0%
|
Ethnicity (NIH/OMB) (Count of Participants) | |||
Hispanic or Latino |
46
21.5%
|
58
28.2%
|
104
24.8%
|
Not Hispanic or Latino |
168
78.5%
|
148
71.8%
|
316
75.2%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
3
1.4%
|
5
2.4%
|
8
1.9%
|
Asian |
0
0%
|
1
0.5%
|
1
0.2%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
Black or African American |
29
13.6%
|
32
15.5%
|
61
14.5%
|
White |
179
83.6%
|
164
79.6%
|
343
81.7%
|
More than one race |
2
0.9%
|
2
1%
|
4
1%
|
Unknown or Not Reported |
1
0.5%
|
2
1%
|
3
0.7%
|
Body Mass Index (BMI) (kg/m^2) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [kg/m^2] |
30.52
(6.184)
|
31.14
(7.567)
|
30.82
(6.896)
|
Skin Category (Fitzpatrick Scale) (Count of Participants) | |||
I (Pale White) |
6
2.8%
|
8
3.9%
|
14
3.3%
|
II (Fair) |
74
34.6%
|
54
26.2%
|
128
30.5%
|
III (Darker White) |
50
23.4%
|
64
31.1%
|
114
27.1%
|
IV (Light Brown) |
53
24.8%
|
47
22.8%
|
100
23.8%
|
V (Brown) |
15
7%
|
18
8.7%
|
33
7.9%
|
VI (Dark Brown) |
16
7.5%
|
15
7.3%
|
31
7.4%
|
Outcome Measures
Title | 2-level Composite Responders for the Target Buttock |
---|---|
Description | Proportion of 2-level Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) / Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) composite responders in the target buttock at Day 71. CR-PCSS and PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-level composite responder is defined as a participant with improvement from baseline of at least 2-levels of severity in the CR-PCSS and an improvement from baseline of at least 2-levels of severity in the PR-PCSS of the target buttock. A participant who missed one or two assessments of CR-PCSS and PR-PCSS at Day 71 was defined as a non-responder. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Yes |
12
5.6%
|
1
0.5%
|
No |
202
94.4%
|
205
99.5%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.002 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 1-level PR-PCSS Responders of the Target Buttock |
---|---|
Description | Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Yes |
124
57.9%
|
61
29.6%
|
No |
90
42.1%
|
145
70.4%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 2-level PR-PCSS Responders of the Target Buttock |
---|---|
Description | Improvement in cellulite severity of the Target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS). PR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Yes |
45
21%
|
12
5.8%
|
No |
169
79%
|
194
94.2%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 1-level Composite Responders of the Target Buttock |
---|---|
Description | Improvement in cellulite severity of the Target Buttock from baseline of at least 1-level of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Yes |
89
41.6%
|
23
11.2%
|
No |
125
58.4%
|
183
88.8%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 2-level Composite Responders of the Non-target Buttock |
---|---|
Description | Improvement in cellulite severity of the Non-target Buttock from baseline of at least 2-levels of severity in Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) / Clinician -Reported Photonumeric Cellulite Severity Scale (CR-PCSS). PR-PCSS and CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Yes |
13
6.1%
|
4
1.9%
|
No |
201
93.9%
|
202
98.1%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.033 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 1-level SSRS Responders |
---|---|
Description | Subject Self-Rating Scale (SSRS) is a measure that assesses participant satisfaction with appearance in association with cellulite on the buttocks using whole numbers on a 7-level scale that ranges from "0" (Extremely Dissatisfied) to "6" (Extremely Satisfied). A 1-level SSRS responder is defined as a participant who is at least slightly satisfied (Slightly Satisfied [4], Very Satisfied [5], or Extremely Satisfied [6]) with the appearance of the cellulite on her buttocks at Day 71. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock (1.68 mg Total Dose) | Placebo-control |
Measure Participants | 214 | 206 |
Count of Participants [Participants] |
90
42.1%
|
31
15%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | Change From Baseline in PR-CIS Total Score |
---|---|
Description | Patient-Reported Cellulite Impact Scale (PR-CIS) is a 6-item static questionnaire, each item is answered by a participant on a 11-level numerical rating scale that ranges from "0" (Not at all) to "10" (Extremely). The PR-CIS total score is the sum of individual item scores and can range from "0" to "60" with higher numbers reflecting a more negative impact from the cellulite. A responder is defined as a participant with a reduction in the PR-CIS total score of at least 12 from baseline at evaluation time point. A negative change from baseline indicates an improvement in cellulite severity. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock (1.68 mg Total Dose) | Placebo-control |
Measure Participants | 214 | 206 |
Baseline (Day 1) |
52.4
(8.01)
|
51.6
(9.40)
|
Day 71 |
40.9
(13.57)
|
45.1
(12.65)
|
Change from Baseline |
-11.5
(12.74)
|
-6.5
(11.74)
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | ANCOVA | |
Comments | With factors of treatment group and analysis center adjusted for baseline values in the model |
Title | 1-level S-GAIS Responders of Target Buttock |
---|---|
Description | Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with ≥1-level improvement (Improved, Much Improved or Very Improved) in S-GAIS assessment of the Target Buttock. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Count of Participants [Participants] |
126
58.9%
|
46
22.3%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | 2-level S-GAIS Responders of Target Buttock |
---|---|
Description | Subject Global Aesthetic Improvement Scale (S-GAIS) is a measure that assesses participant rating of cellulite appearance after treatment. This scale has 7-levels ranging from "+3" (Very Much Improved) to "-3" (Very Much Worse). Responders are defined as participants with ≥ 2-level improvement (Much Improved or Very Much Improved) in S-GAIS assessment of the Target Buttock. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
ITT Population includes all randomized participants who had at least 1 injection of study drug. All demographic and baseline characteristic summaries were based on this population. The primary and key secondary efficacy parameters were summarized based on this population. |
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo |
---|---|---|
Arm/Group Description | CCH 0.84 mg/Buttock | Placebo-control |
Measure Participants | 214 | 206 |
Count of Participants [Participants] |
38
17.8%
|
9
4.4%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Collagenase Clostridium Histolyticum (CCH), Placebo |
---|---|---|
Comments | CCH 0.84 mg/Buttock versus Placebo | |
Type of Statistical Test | Superiority | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.001 |
Comments | ||
Method | Cochran-Mantel-Haenszel | |
Comments | Adjusted for analysis center |
Title | PR-PCSS Rating for the Target and Non-target Buttock by Visit |
---|---|
Description | The Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level photonumeric scale used by the patient (participant) to assess the severity of the participant's cellulite. The ratings range from "0" (None) to "4" (Severe). |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population. |
Arm/Group Title | Day 1: CCH | Day 1: Placebo | Day 22: CCH | Day 22: Placebo | Day 43: CCH | Day 43: Placebo | Day 71: CCH | Day 71: Placebo | Day 71: CCH (LOCF) | Day 71: Placebo (LOCF) |
---|---|---|---|---|---|---|---|---|---|---|
Arm/Group Description | Baseline (Day 1) for CCH Treated Group | Baseline (Day 1) for PlaceboGroup | Day 22 for CCH Treated Group | Day 22 for Placebo Group | Day 43 for CCH Treated Group | Day 43 for Placebo Group | Day 71 for CCH Treated Group | Day 71 for Placebo Group | Day 71 for CCH Treated Group (Last Observation Carried Forward) | Day 71 for Placebo Group (Last Observation Carried Forward) |
Measure Participants | 209 | 201 | 209 | 201 | 209 | 201 | 209 | 201 | 209 | 201 |
None (0) |
0
0%
|
0
0%
|
0
0%
|
1
NaN
|
0
NaN
|
0
NaN
|
3
NaN
|
0
NaN
|
3
NaN
|
0
NaN
|
Almost None (1) |
0
0%
|
0
0%
|
1
0.2%
|
1
NaN
|
17
NaN
|
3
NaN
|
19
NaN
|
2
NaN
|
19
NaN
|
2
NaN
|
Mild (2) |
0
0%
|
0
0%
|
45
10.7%
|
17
NaN
|
61
NaN
|
26
NaN
|
61
NaN
|
32
NaN
|
64
NaN
|
32
NaN
|
Moderate (3) |
89
41.6%
|
82
39.8%
|
78
18.6%
|
79
NaN
|
67
NaN
|
85
NaN
|
65
NaN
|
76
NaN
|
76
NaN
|
81
NaN
|
Severe (4) |
120
56.1%
|
119
57.8%
|
73
17.4%
|
101
NaN
|
41
NaN
|
77
NaN
|
38
NaN
|
81
NaN
|
47
NaN
|
86
NaN
|
None (0) |
0
0%
|
0
0%
|
0
0%
|
1
NaN
|
0
NaN
|
0
NaN
|
1
NaN
|
0
NaN
|
1
NaN
|
0
NaN
|
Almost None (1) |
0
0%
|
0
0%
|
3
0.7%
|
0
NaN
|
17
NaN
|
4
NaN
|
21
NaN
|
3
NaN
|
21
NaN
|
3
NaN
|
Mild (2) |
0
0%
|
0
0%
|
38
9%
|
19
NaN
|
55
NaN
|
24
NaN
|
58
NaN
|
32
NaN
|
64
NaN
|
34
NaN
|
Moderate (3) |
96
44.9%
|
71
34.5%
|
82
19.5%
|
71
NaN
|
67
NaN
|
86
NaN
|
66
NaN
|
72
NaN
|
74
NaN
|
75
NaN
|
Severe (4) |
113
52.8%
|
130
63.1%
|
74
17.6%
|
108
NaN
|
47
NaN
|
77
NaN
|
40
NaN
|
84
NaN
|
49
NaN
|
89
NaN
|
Title | Subjects Satisfaction With Cellulite Treatment |
---|---|
Description | A 1-level Subject Satisfaction Responder is defined as a participant who is at least satisfied (Satisfied [+1], or Very Satisfied [+2]) with the appearance of the cellulite on her buttocks at the Day 71 visit. A positive change indicates an improvement in cellulite. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
mITT Population includes all ITT participants with a baseline and at least 1 post-injection evaluation of both the CR-PCSS and PR-PCSS for both the target and non-target buttocks. All secondary and supportive efficacy evaluations were based on the mITT Population. |
Arm/Group Title | Day 71: CCH | Day 71: Placebo | Day 71: CCH (LOCF) | Day 71: Placebo (LOCF) |
---|---|---|---|---|
Arm/Group Description | Day 71 for CCH Treated Group | Day 71 for Placebo Group | Day 71 for CCH Treated Group (Last Observation Carried Forward) | Day 71 for Placebo Group (Last Observation Carried Forward) |
Measure Participants | 186 | 191 | 198 | 195 |
Very Satisfied (+2) |
15
7%
|
4
1.9%
|
15
3.6%
|
4
NaN
|
Satisfied (+1) |
72
33.6%
|
22
10.7%
|
74
17.6%
|
22
NaN
|
Neither Satisfied Nor Dissatisfied (0) |
60
28%
|
73
35.4%
|
64
15.2%
|
75
NaN
|
Dissatisfied (-1) |
24
11.2%
|
47
22.8%
|
29
6.9%
|
48
NaN
|
Very Dissatisfied (-2) |
15
7%
|
45
21.8%
|
16
3.8%
|
46
NaN
|
Title | Serum Antibody Positivity by Visit |
---|---|
Description | Percent of participants that are seropositive. Percentages were based on the number of subjects who had immunogenicity lab samples analyzed at the visit. |
Time Frame | Day 1 - Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population. |
Arm/Group Title | Anti-AUX-I: CCH | Anti-AUX-I: Placebo | Anti-AUX-II: CCH | Anti-AUX-II: Placebo |
---|---|---|---|---|
Arm/Group Description | Antibody AUX-I for the CCH Treated Group | Antibody AUX-I for the Placebo Group | Antibody AUX-II for the CCH Treated Group | Antibody AUX-II for the Placebo Group |
Measure Participants | 214 | 206 | 214 | 206 |
Seropositive |
6
2.8%
|
2
1%
|
3
0.7%
|
6
NaN
|
Seronegative |
208
97.2%
|
204
99%
|
211
50.2%
|
200
NaN
|
Seropositive |
106
49.5%
|
1
0.5%
|
52
12.4%
|
7
NaN
|
Seronegative |
90
42.1%
|
198
96.1%
|
144
34.3%
|
192
NaN
|
Seropositive |
183
85.5%
|
4
1.9%
|
183
43.6%
|
7
NaN
|
Seronegative |
3
1.4%
|
186
90.3%
|
3
0.7%
|
183
NaN
|
Seropositive |
186
86.9%
|
8
3.9%
|
185
44%
|
9
NaN
|
Seronegative |
0
0%
|
182
88.3%
|
1
0.2%
|
181
NaN
|
Title | Overall Antibody Titer Levels by Visit |
---|---|
Description | Descriptive statistics were based on log10 transformation of titer levels. Titer levels were imputed as 10 before the transformation if the reported level is "<10". Only seropositive participants are summarized. |
Time Frame | Day 1 - Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population. |
Arm/Group Title | Anti-AUX-I: CCH | Anti-AUX-I: Placebo | Anti-AUX-II: CCH | Anti-AUX-II: Placebo |
---|---|---|---|---|
Arm/Group Description | Antibody AUX-I for the CCH Treated Group | Antibody AUX-I for the Placebo Group | Antibody AUX-II for the CCH Treated Group | Antibody AUX-II for the Placebo Group |
Measure Participants | 214 | 206 | 214 | 206 |
Day 1 positive |
2.235
(1.7365)
|
1.000
(0.0000)
|
3.212
(0.8056)
|
1.365
(0.3834)
|
Day 22 positive |
2.331
(1.2566)
|
3.504
|
1.912
(1.2718)
|
1.387
(0.4788)
|
Day 43 positive |
4.602
(0.8721)
|
2.539
(1.1462)
|
3.680
(1.0617)
|
1.302
(0.4596)
|
Day 71 positive |
5.898
(0.7131)
|
2.039
(1.2854)
|
5.255
(0.7142)
|
1.572
(0.7895)
|
Title | Presence of Neutralizing Antibody (Seropositivity) at Day 71 (LOCF) by Antidrug Antibody Log Titer Quartiles |
---|---|
Description | Q1 and Q4 are based on the ADA titer levels. |
Time Frame | Day 71 |
Outcome Measure Data
Analysis Population Description |
---|
Safety Population includes all participants who received at least 1 dose of CCH in this study. All safety parameters were summarized based on this population. |
Arm/Group Title | CCH: Q1 | CCH: Q4 | CCH: Total |
---|---|---|---|
Arm/Group Description | Q1 for the CCH Treated Group | Q4 for the CCH Treated Group | Total CCH |
Measure Participants | 24 | 24 | 48 |
Negative |
12
5.6%
|
3
1.5%
|
15
3.6%
|
Positive |
12
5.6%
|
21
10.2%
|
33
7.9%
|
Negative |
5
2.3%
|
1
0.5%
|
6
1.4%
|
Positive |
19
8.9%
|
23
11.2%
|
42
10%
|
Adverse Events
Time Frame | All (serious and nonserious) AEs, from Day 1 to Day 71 | |||
---|---|---|---|---|
Adverse Event Reporting Description | All (serious and nonserious) AEs, whether elicited or observed during study visits or spontaneously reported by the participant, including events that occurred from the time the participant signed the study-specific consent form until completion of or discharge from the study. | |||
Arm/Group Title | Collagenase Clostridium Histolyticum (CCH) | Placebo | ||
Arm/Group Description | CCH 0.84 mg/Buttock 1.68 mg Total Dose | Placebo-control | ||
All Cause Mortality |
||||
Collagenase Clostridium Histolyticum (CCH) | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/214 (0%) | 0/206 (0%) | ||
Serious Adverse Events |
||||
Collagenase Clostridium Histolyticum (CCH) | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 1/214 (0.5%) | 0/206 (0%) | ||
Metabolism and nutrition disorders | ||||
Hypokalemia | 1/214 (0.5%) | 0/206 (0%) | ||
Nervous system disorders | ||||
Syncope | 1/214 (0.5%) | 0/206 (0%) | ||
Vascular disorders | ||||
Hypotension | 1/214 (0.5%) | 0/206 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
Collagenase Clostridium Histolyticum (CCH) | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 203/214 (94.9%) | 64/206 (31.1%) | ||
General disorders | ||||
Injection site bruising | 193/214 (90.2%) | 42/206 (20.4%) | ||
Injection site pain | 127/214 (59.3%) | 26/206 (12.6%) | ||
Injection site nodule | 70/214 (32.7%) | 2/206 (1%) | ||
Injection site pruritus | 34/214 (15.9%) | 3/206 (1.5%) | ||
Injection site erythema | 28/214 (13.1%) | 17/206 (8.3%) | ||
Injection site discolouration | 21/214 (9.8%) | 2/206 (1%) | ||
Injection site mass | 15/214 (7%) | 0/206 (0%) | ||
Injection site warmth | 13/214 (6.1%) | 0/206 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Saji Vijayan, MBBS |
---|---|
Organization | Endo Pharmaceuticals |
Phone | 800-462-3636 |
ClinicalTrials@Endo.com |
- EN3835-303